[go: up one dir, main page]

WO2002013843A3 - Chemotherapeutic agents conjugated to p97 and their methods of use in treating neurological tumours - Google Patents

Chemotherapeutic agents conjugated to p97 and their methods of use in treating neurological tumours Download PDF

Info

Publication number
WO2002013843A3
WO2002013843A3 PCT/CA2001/001158 CA0101158W WO0213843A3 WO 2002013843 A3 WO2002013843 A3 WO 2002013843A3 CA 0101158 W CA0101158 W CA 0101158W WO 0213843 A3 WO0213843 A3 WO 0213843A3
Authority
WO
WIPO (PCT)
Prior art keywords
chemotherapeutic agents
methods
treating neurological
agents conjugated
pharmaceutical compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CA2001/001158
Other languages
French (fr)
Other versions
WO2002013843A2 (en
Inventor
Reinhard Gabathuler
Gerrassimos Kolaitis
Robert Charles Brooks
Qingqi Chen
Delara M Karkan
Gavin D Arthur
Pierre Jean Paul St
Wilfred Jeffries
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of British Columbia
Original Assignee
University of British Columbia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of British Columbia filed Critical University of British Columbia
Priority to AU2001283740A priority Critical patent/AU2001283740A1/en
Publication of WO2002013843A2 publication Critical patent/WO2002013843A2/en
Publication of WO2002013843A3 publication Critical patent/WO2002013843A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/644—Transferrin, e.g. a lactoferrin or ovotransferrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention provides pharmaceutical compositions of chemotherapeutic agents that demonstrate therapeutic efficacy against brain tumours and other neoplasia localized in or around the brain. In certain aspects, the pharmaceutical compositions comprise a chemotherapeutic agent conjugated to p97; and a pharmaceutically acceptable carrier therefor. Preferred chemotherapeutic agents include, but are not limited to, adriamycin, cisplatin, and paclitaxel.
PCT/CA2001/001158 2000-08-17 2001-08-17 Chemotherapeutic agents conjugated to p97 and their methods of use in treating neurological tumours Ceased WO2002013843A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001283740A AU2001283740A1 (en) 2000-08-17 2001-08-17 Chemotherapeutic agents conjugated to p97 and their methods of use in treating neurological tumours

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22625400P 2000-08-17 2000-08-17
US60/226,254 2000-08-17

Publications (2)

Publication Number Publication Date
WO2002013843A2 WO2002013843A2 (en) 2002-02-21
WO2002013843A3 true WO2002013843A3 (en) 2002-12-12

Family

ID=22848166

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CA2001/001158 Ceased WO2002013843A2 (en) 2000-08-17 2001-08-17 Chemotherapeutic agents conjugated to p97 and their methods of use in treating neurological tumours

Country Status (2)

Country Link
AU (1) AU2001283740A1 (en)
WO (1) WO2002013843A2 (en)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1554572B1 (en) 2001-07-25 2009-10-14 Raptor Pharmaceutical Inc. Compositions and methods for modulating blood-brain barrier transport
US7265084B2 (en) 2001-10-10 2007-09-04 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
US7125843B2 (en) 2001-10-19 2006-10-24 Neose Technologies, Inc. Glycoconjugates including more than one peptide
US7795210B2 (en) 2001-10-10 2010-09-14 Novo Nordisk A/S Protein remodeling methods and proteins/peptides produced by the methods
US7214660B2 (en) 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
EP2292273A3 (en) 2001-10-10 2011-11-23 BioGeneriX AG Remodeling and glycoconjugation of peptides
US7265085B2 (en) 2001-10-10 2007-09-04 Neose Technologies, Inc. Glycoconjugation methods and proteins/peptides produced by the methods
US7179617B2 (en) 2001-10-10 2007-02-20 Neose Technologies, Inc. Factor IX: remolding and glycoconjugation of Factor IX
US7399613B2 (en) 2001-10-10 2008-07-15 Neose Technologies, Inc. Sialic acid nucleotide sugars
US7297511B2 (en) 2001-10-10 2007-11-20 Neose Technologies, Inc. Interferon alpha: remodeling and glycoconjugation of interferon alpha
US8008252B2 (en) 2001-10-10 2011-08-30 Novo Nordisk A/S Factor VII: remodeling and glycoconjugation of Factor VII
US7173003B2 (en) 2001-10-10 2007-02-06 Neose Technologies, Inc. Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
US7439043B2 (en) 2001-10-10 2008-10-21 Neose Technologies, Inc. Galactosyl nucleotide sugars
US7157277B2 (en) 2001-11-28 2007-01-02 Neose Technologies, Inc. Factor VIII remodeling and glycoconjugation of Factor VIII
US7696163B2 (en) 2001-10-10 2010-04-13 Novo Nordisk A/S Erythropoietin: remodeling and glycoconjugation of erythropoietin
US7226903B2 (en) 2001-10-10 2007-06-05 Neose Technologies, Inc. Interferon beta: remodeling and glycoconjugation of interferon beta
US7473680B2 (en) 2001-11-28 2009-01-06 Neose Technologies, Inc. Remodeling and glycoconjugation of peptides
EP2399586A1 (en) 2002-01-11 2011-12-28 Jefferies, Dr., Wilfred Use of P97 as an enzyme delivery system for the delivery of therapeutic lysosomal enzymes
WO2004008101A2 (en) * 2002-07-12 2004-01-22 Biomarin Pharmaceutical Inc. The use of isocyanate linkers to make hydrolyzable active agent biopolymer conjugates
EP1608688B1 (en) 2003-03-14 2013-02-27 BioGeneriX AG Branched water-soluble polymers and their conjugates
MXPA05010773A (en) 2003-04-09 2005-12-12 Neose Technologies Inc Glycopegylation methods and proteins/peptides produced by the methods.
US8791070B2 (en) 2003-04-09 2014-07-29 Novo Nordisk A/S Glycopegylated factor IX
WO2004091499A2 (en) 2003-04-09 2004-10-28 Neose Technologies, Inc. Intracellular formation of peptide conjugates
CA2524936A1 (en) 2003-05-09 2004-12-02 Neose Technologies, Inc. Compositions and methods for the preparation of human growth hormone glycosylation mutants
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
US20050026823A1 (en) 2003-06-20 2005-02-03 Biomarin Pharmaceutical Inc. Use of the chaperone receptor-associated protein (RAP) for the delivery of therapeutic compounds to the brain and other tissues
WO2005012484A2 (en) 2003-07-25 2005-02-10 Neose Technologies, Inc. Antibody-toxin conjugates
MXPA06005732A (en) 2003-11-24 2006-08-17 Neose Technologies Inc Glycopegylated erythropoietin.
US8633157B2 (en) 2003-11-24 2014-01-21 Novo Nordisk A/S Glycopegylated erythropoietin
US20080305992A1 (en) 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
US7956032B2 (en) 2003-12-03 2011-06-07 Novo Nordisk A/S Glycopegylated granulocyte colony stimulating factor
US20060040856A1 (en) 2003-12-03 2006-02-23 Neose Technologies, Inc. Glycopegylated factor IX
BRPI0506741A (en) 2004-01-08 2007-05-15 Neose Technologies Inc glycosylation of peptides linked to the
EP1730174B1 (en) 2004-03-05 2010-04-21 The Board Of Trustees Of The University Of Illinois Peptide carrier for drug delivery
WO2005111225A1 (en) 2004-05-04 2005-11-24 Novo Nordisk Health Care Ag O-linked glycoforms of polypeptides and method to manufacture them
WO2006010143A2 (en) 2004-07-13 2006-01-26 Neose Technologies, Inc. Branched peg remodeling and glycosylation of glucagon-like peptide-1 [glp-1]
WO2006031811A2 (en) 2004-09-10 2006-03-23 Neose Technologies, Inc. Glycopegylated interferon alpha
CA2585758C (en) 2004-10-29 2017-08-01 Neose Technologies, Inc. Remodeling and glycopegylation of fibroblast growth factor (fgf)
MX2007008229A (en) 2005-01-10 2007-09-11 Neose Technologies Inc Glycopegylated granulocyte colony stimulating factor.
JP4896959B2 (en) 2005-03-30 2012-03-14 サラダックス バイオメディカル インク． Doxorubicin immunoassay
EP1871795A4 (en) 2005-04-08 2010-03-31 Biogenerix Ag Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
WO2006127910A2 (en) 2005-05-25 2006-11-30 Neose Technologies, Inc. Glycopegylated erythropoietin formulations
EP2975135A1 (en) 2005-05-25 2016-01-20 Novo Nordisk A/S Glycopegylated factor IX
EP1745802A1 (en) * 2005-07-20 2007-01-24 Kreatech Biotechnology B.V. Method of conjugating therapeutic compounds to cell targeting moieties via metal complexes
US20070105755A1 (en) 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
US20090048440A1 (en) 2005-11-03 2009-02-19 Neose Technologies, Inc. Nucleotide Sugar Purification Using Membranes
EP2049144B8 (en) 2006-07-21 2015-02-18 ratiopharm GmbH Glycosylation of peptides via o-linked glycosylation sequences
EP2054521A4 (en) 2006-10-03 2012-12-19 Novo Nordisk As METHODS OF PURIFYING CONJUGATES OF POLYPEPTIDES
KR20100016160A (en) 2007-04-03 2010-02-12 바이오제너릭스 에이지 Methods of treatment using glycopegylated g-csf
EP2170919B8 (en) 2007-06-12 2016-01-20 ratiopharm GmbH Improved process for the production of nucleotide sugars
US8207112B2 (en) 2007-08-29 2012-06-26 Biogenerix Ag Liquid formulation of G-CSF conjugate
EP2257311B1 (en) 2008-02-27 2014-04-16 Novo Nordisk A/S Conjugated factor viii molecules
JP6208658B2 (en) 2011-07-05 2017-10-04 バイオアシス テクノロジーズ インコーポレイテッド p97-antibody conjugates and methods of use
PL2739649T3 (en) 2011-08-05 2018-03-30 Bioasis Technologies Inc. Fragmenty p97 o aktywności transferowej
ES2647082T3 (en) 2012-07-31 2017-12-19 Bioasis Technologies Inc Dephosphorylated proteins of lysosomal deposition disease and methods of use thereof
EP2970433B1 (en) 2013-03-13 2019-09-18 Bioasis Technologies Inc. Fragments of p97 and uses thereof
RU2665688C2 (en) * 2013-04-12 2018-09-04 Общество С Ограниченной Ответственностью "Фарминтерпрайсез" Dicarboxylic acid bisamide derivatives, their application, the pharmaceutical composition on their basis, methods for their production
BR112016017933A2 (en) 2014-02-03 2017-10-10 Bioasis Technologies Inc ? p97 fusion proteins?
US10392605B2 (en) 2014-02-19 2019-08-27 Bioasis Technologies Inc. P97-IDS fusion proteins

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2116979A (en) * 1982-02-25 1983-10-05 Ward Page Faulk Conjugates of proteins with anti- tumour agents
EP0457250A2 (en) * 1990-05-14 1991-11-21 Bristol-Myers Squibb Company Novel bifunctional linking compounds, conjugates and methods for their production
DE4122210A1 (en) * 1991-07-04 1993-01-14 Deutsches Krebsforsch CONJUGATES OF TUMORACTIVE COMPOUND AND PROTEIN AND METHOD FOR THE PRODUCTION THEREOF AND THEIR USE
WO1994001463A1 (en) * 1992-07-10 1994-01-20 University Of British Columbia USE OF p97 AND IRON BINDING PROTEINS AS DIAGNOSTIC AND THERAPEUTIC AGENTS
WO2001059459A2 (en) * 2000-02-08 2001-08-16 University Of British Columbia Compositions and methods for screening therapeutic agents

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2116979A (en) * 1982-02-25 1983-10-05 Ward Page Faulk Conjugates of proteins with anti- tumour agents
EP0457250A2 (en) * 1990-05-14 1991-11-21 Bristol-Myers Squibb Company Novel bifunctional linking compounds, conjugates and methods for their production
DE4122210A1 (en) * 1991-07-04 1993-01-14 Deutsches Krebsforsch CONJUGATES OF TUMORACTIVE COMPOUND AND PROTEIN AND METHOD FOR THE PRODUCTION THEREOF AND THEIR USE
WO1994001463A1 (en) * 1992-07-10 1994-01-20 University Of British Columbia USE OF p97 AND IRON BINDING PROTEINS AS DIAGNOSTIC AND THERAPEUTIC AGENTS
WO2001059459A2 (en) * 2000-02-08 2001-08-16 University Of British Columbia Compositions and methods for screening therapeutic agents

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
BEYER U ET AL: "Synthesis and in vitro efficacy of transferrin conjugates of the anticancer drug chlorambucil", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 41, no. 15, 25 June 1998 (1998-06-25), pages 2701 - 2708, XP002170971, ISSN: 0022-2623 *
BEYER U ET AL: "SYNTHESIS OF TRANSFERRIN AND ALBUMIN CONJUGATES OF THE ANCICANCER DRUGS CHLORAMBUCIL, DOXURUBICIN AND DAUNORUBICIN", EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, ELSEVIER, AMSTERDAM, NL, vol. 4, no. SUPPL, 1996, pages S111, XP002062901, ISSN: 0928-0987 *
BICAMUMPAKA C ET AL: "IN VITRO CYTOTOXICITY OF PACLITAXEL-TRANSFERRIN CONJUGATE ON H69 CELLS", ONCOLOGY REPORTS, NATIONAL HELLENIC RESEARCH FOUNDATION, ATHENS, GR, vol. 5, no. 5, November 1998 (1998-11-01), pages 1381 - 1383, XP001094446, ISSN: 1021-335X *
KRATZ F ET AL: "Synthesis of new maleimide derivatives of daunorubicin and biological activity of acid labile transferrin conjugates", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, OXFORD, GB, vol. 7, no. 5, 4 March 1997 (1997-03-04), pages 617 - 622, XP004136076, ISSN: 0960-894X *
KRATZ F ET AL: "TRANSFERRIN CONJUGATES OF DOXORUBICIN: SYNTHESIS, CHARACTERIZATION,CELLULAR UPTAKE, AND IN VITRO EFFICACY", JOURNAL OF PHARMACEUTICAL SCIENCES, AMERICAN PHARMACEUTICAL ASSOCIATION. WASHINGTON, US, vol. 87, no. 3, 1 March 1998 (1998-03-01), pages 338 - 346, XP000736343, ISSN: 0022-3549 *
ROSE T M ET AL: "PRIMARY STRUCTURE OF THE HUMAN MELANOMA-ASSOCIATED ANTIGEN P97 (MELANOTRANSFERRIN) DEDUCED FROM THE MRNA SEQUENCE", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 83, March 1986 (1986-03-01), pages 1261 - 1265, XP002934311, ISSN: 0027-8424 *
TANAKA T ET AL: "SYNTHESIS OF TRANSFERRIN-MITOMYCIN C CONJUGATE AS A RECEPTOR- MEDIATED DRUG TARGETING SYSTEM", BIOLOGICAL & PHARMACEUTICAL BULLETIN (OF JAPAN), PHARMACEUTICAL SOCIETY OF JAPAN, JP, vol. 19, no. 5, 1 May 1996 (1996-05-01), pages 774 - 777, XP000594655, ISSN: 0918-6158 *

Also Published As

Publication number Publication date
WO2002013843A2 (en) 2002-02-21
AU2001283740A1 (en) 2002-02-25

Similar Documents

Publication Publication Date Title
WO2002013843A3 (en) Chemotherapeutic agents conjugated to p97 and their methods of use in treating neurological tumours
WO2002013873A3 (en) P97-active agent conjugates and their methods of use
WO2002002077A3 (en) Liposomal antineoplastic drugs and uses thereof
AU7445901A (en) Pharmaceutical compositions comprising cannabidiol derivatives
WO2000006134A3 (en) Use of l-carnitine and its alkanoyl derivatives in the preparation of medicaments with anticancer activity
MXPA02012068A (en) Liposomal benzoquinazoline thymidylate synthase inhibitor formulations.
AU2002236765A1 (en) Pharmaceutical combination for the treatment of cancer containing a 4-quinazolineamine and another anti-neoplastic agent
WO2004111192A3 (en) Targeted delivery to legumain-expressing cells
WO2001068145A3 (en) Peptidase-cleavable, targeted antineoplastic drugs and their therapeutic use
WO2001078783A3 (en) Compositions comprising natural agents for treatment of cancer
WO2000066093A3 (en) Combined preparations comprising morpholine anthracyclines and anticancer agent
WO2006043083A3 (en) Liposomes enclosing a radionuclide and a cytotoxic agent for combination therapy
HK1041209A1 (en) A composition and method for the enhancement of the efficacy of drugs
GB2368525B (en) Hyaluronan as a cytotoxic agent, drug pre-sensitizer and chemo-sensitizer in the treatment of disease
AU2002226030A1 (en) Cytotoxic t-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
EP1201247A3 (en) Treatment of tumor metastases and cancer
WO2002102311A3 (en) Nanoparticles for treating targeted tissues and cells
AU2002347747A1 (en) Retinol derivatives, their use in the treatment of cancer and for potentiating the efficacy of other cytotoxic agents
WO2003008637A3 (en) Use of genotyping in the individualization of therapy
CA2363973A1 (en) Enhancement of effectiveness of 5-fluorouracil in treatment of tumor metastases and cancer
EP1263749A4 (en) Taxane anticancer agents
WO2001070184A3 (en) A composition containing monoterpenes for topical oral administration
WO2004093916A8 (en) A medicament for the two-step perioperative therapy of solid tumours
WO2002076393A3 (en) Antiagionecic, antitumor, chemopreventative agents
WO2003020371A3 (en) Potentiator composition comprising a terpene for enhancing a therapeutical effect of antitumoral agents in the treatment of cancer

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP